Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster

Cancers(2022)10.3390/cancers14225537Source: DataRank Database

Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.39)OA: goldTopics (20)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Magdalena Corona ORCID,Sara Rodríguez-Mora ORCID,Guiomar Casado‐Fernández ORCID,Alejandro Zurdo-Castronuño,Elena Mateos ORCID

Live enrichment

PubMed:36428631 PMC:PMC9688562 OpenAlex:https://openalex.org/W4308867592

Strategic Action in Health 2017–2020 of the Instituto de Salud Carlos III

Grant: PI21/00877

Strategic Action in Health 2017–2020 of the Instituto de Salud Carlos III

Grant: COV20_00679

Strategic Action in Health 2017–2020 of the Instituto de Salud Carlos III

Grant: R01AI143567

Strategic Action in Health 2017–2020 of the Instituto de Salud Carlos III

Grant: PID2019-110275RB-I00

Chiesi Foundation

Grant: Donation

FWCI

0.39

Citation Percentile

0.6%

Citation Trend

2023

2024

2025

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/14/22/5537/pdf?version=1668658448

publisherhttps://www.mdpi.com/2072-6694/14/22/5537/pdf?version=1668658448

publisherhttps://www.mdpi.com/2072-6694/14/22/5537/pdf

journalhttps://doi.org/10.3390/cancers14225537

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36428631

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmunotherapy and Immune Responses

Keywords

MedicineRituximabImmunologyImmune systemAntibody-dependent cell-mediated cytotoxicityAntibodySeroconversionCD20Peripheral blood mononuclear cellMonoclonal antibodyBiologyIn vitroHumoral responseHematological malignanciesAnti-cd20Cytotoxic ResponseCovid-19 Vaccine

Sustainable Development Goals

SDG 0: Good health and well-being

Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster

FAIR Checklist

Authors (16)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)